Skip to main content

Table 4 All-cause and neutropenia-related utilization by cycle

From: Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

  

Total (N = 12,056)

Filgrastim (N = 373)

Pegfilgrastim (N = 11,683)

All-cause

Hospitalizations n (%)*

620 (5.1)

38 (10.2)

582 (5.0)

Mean ± SD

0.06 ± 0.26

0.14 ± 0.46

0.05 ± 0.25

Ambulatory visits n (%)*

12,051 (100)

373 (100)

11,678 (100)

Mean ± SD

5.5 ± 3.7

9.5 ± 5.9

5.4 ± 3.5

Emergency room visits n (%)*

943 (7.8)

27 (7.2)

916 (7.8)

Mean ± SD

0.11 ± 0.46

0.09 ± 0.32

0.11 ± 0.46

Neutropenia- related

Hospitalizations n (%)*

73 (0.61)

5 (1.34)

68 (0.58)

Mean ± SD

0.01 ± 0.08

0.02 ± 0.17

0.01 ± 0.08

Ambulatory visits n (%)*

3,422 (28.4)

148 (39.7)

3,274 (28.0)

Mean ± SD

0.42 ± 0.93

2.1 ± 3.3

0.36 ± 0.68

Emergency room visits n (%)*

32 (0.27)

1 (0.27)

31 (0.27)

Mean ± SD

0.00 ± 0.05

0.00 ± 0.05

0.00 ± 0.05

  1. * Number of cycles with the event and percentage of those cycles among all cycles.
  2. Mean and standard deviation of the number of events per cycle.